Methadone and Tizanidine

Phase 1Small molecule

IIndiana University

Methadone and Tizanidine is one of 54 small molecule programs targeting Interaction. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

InteractionRecruiting

InteractionPhase 1

Recruiting

Competition

Competitive Landscape

62 competitors in Interaction

#DrugCompanyPhaseTrials

Estrace

Novo Nordisk

Approved

2 2

Robitussin

Pfizer

Phase 3

10 3

Epsom Salt

FFresenius Kabi USA, LLC

Approved

1 4

Rifadin

Sanofi

Phase 2

34 5

Sporanox

SSebela Pharmaceuticals Development LLC

Phase 2

77 6

Rifampicin

Boehringer Ingelheim

Phase 3

22 7

Crestor

AstraZeneca

Phase 1

61 8

Tegretol

Novartis

Phase 1

16 9

Lanoxin

Oxycontin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Study completion

NCT05789173

Clinical

Trials by Indication[1]

Unspecified1 trial

Effect of CYP2B6 Genotype and Efavirenz on the Disposition and Pharmacodynamic of Methadone and Tizanidine in Healthy Volunteers

Recruiting·IIndiana University·Phase 1·NCT05789173·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Methadone and Tizanidine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Methadone and Tizanidine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Methadone and Tizanidine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Indiana University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: IIndiana University

Methadone and Tizanidine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Unspecified1 trial

References

Drug Info

Quick Facts

Related News